Aaron Ellenbogen

Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease

Joseph Jankovic, Ira Goodman, Beth Safirstein et al. · JAMA Neurology · 2018 · 283 citations · Full text

Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson’s disease

Danna Jennings, Sarah Huntwork‐Rodriguez, Anastasia G. Henry et al. · Science Translational Medicine · 2022 · 230 citations

Randomized phase I clinical trial of anti–α‐synuclein antibody BIIB054

Laura Fanning, Serena Hung, Aaron Ellenbogen et al. · Movement Disorders · 2019 · 187 citations · Full text

Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS

Clete A. Kushida, Philip M. Becker, Aaron Ellenbogen et al. · Neurology · 2009 · 114 citations

Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial

Daniel K. Burns, Robert Alexander, Kathleen A. Welsh‐Bohmer et al. · The Lancet Neurology · 2021 · 108 citations

Neurodegenerative Diseases, Neuropsychology, Alzheimer's Disease +11